Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Piramal Pharma’s Ahmedabad facility completes USFDA PAI

Piramal Pharma posts Q1 FY24 consolidated PAT at Rs. 101.27 Cr

Piramal Pharma has reported total income of Rs. 2,578.74 crores during the period ended March 31, 2024

Piramal Pharma launches new campaign for 'Polycrol' with Brand Ambassador Jisshu Sengupta

the campaign emphasizes the brand's reliability and effectiveness in providing timely relief

Piramal Pharma forays into men's grooming market in India with the launch of BOHEM

Piramal Pharma gets Form 483 with 2 observations from USFDA for Lexington, USA facility

The observations do not pose any risk to site's compliance standards or its business continuity

Piramal Pharma launches in-vitro biology capabilities at Ahmedabad discovery services site

Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening

USFDA inspection at Piramal Pharma’s Bethlehem facility

Piramal Pharma posts Q1 FY24 consolidated loss at Rs. 98.58 Cr

The company has reported total income of Rs. 1787.16 crores during the period ended June 30, 2023

Piramal Critical Care appoints Jeffrey Hampton as President & COO

Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy